Pancreatic Ductal Adenocarcinoma Clinical Trials and Pipeline 2025: EMA, PDMA, FDA Approvals, Medication, NDA Approval, Therapies, ROA, MOA and Companies by DelveInsight

(Albany, USA) DelveInsight's, "Pancreatic Ductal Adenocarcinoma Pipeline Insight 2025" report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Pancreatic Ductal Adenocarcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Pancreatic Ductal Adenocarcinoma Research. Learn more about our innovative pipeline today! @ Pancreatic Ductal Adenocarcinoma Pipeline Outlook- https://www.delveinsight.com/sample-request/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Takeaways from the Pancreatic Ductal Adenocarcinoma Pipeline Report
• In December 2024:- Genentech Inc.- The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (mFOLFIRINOX) versus mFOLFIRINOX alone in participants with resected pancreatic ductal adenocarcinoma (PDAC) who have not received prior systemic anti-cancer treatment for PDAC and have no evidence of disease after surgery.
• In December 2024:- Revolution Medicines Inc.- This is a global, randomized, open-label, Phase 3 study designed to evaluate whether treatment with RMC-6236 will improve progression free survival (PFS) or overall survival (OS) compared to Investigator's choice of standard of care chemotherapy in patients with metastatic PDAC who were previously treated with one prior line of therapy with 5-fluorouracil (5-FU) based or gemcitabine-based regimen.
• DelveInsight's Pancreatic Ductal Adenocarcinoma pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Pancreatic Ductal Adenocarcinoma treatment.
• The leading Pancreatic Ductal Adenocarcinoma Companies such as Cardiff Oncology, XOMA, Alphamab, Cantargia, RenovoRx, Syntrix Biosystems, Eucure Biopharma, Panbela Therapeutics, Jeil Pharmaceutical, Elicio Therapeutics, Cend Therapeutics, SignalChem Lifesciences, Bristol-Myers Squibb, AstraZeneca, REVOLUTION Medicines, Arcus Biosciences, ZielBio, Surface Oncology, Incyte Corporation, I-Mab Biopharma, Medicenna Therapeutics, Tarveda Therapeutics, and others.
• Promising Pancreatic Ductal Adenocarcinoma Therapies such as Zimberelimab, Quemliclustat, Onvansertib, Nanoliposomal irinotecan, Leucovorin, mFOLFIRINOX, and others.

Stay informed about the cutting-edge advancements in Pancreatic Ductal Adenocarcinoma Treatments. Download for updates and be a part of the revolution in oncology care @ Pancreatic Ductal Adenocarcinoma Clinical Trials Assessment- https://www.delveinsight.com/sample-request/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Pancreatic Ductal Adenocarcinoma Overview:
Pancreatic Ductal Adenocarcinoma (PDAC) is the most common and aggressive form of pancreatic cancer, originating in the ductal cells of the pancreas. It accounts for over 90% of pancreatic malignancies and is often diagnosed at an advanced stage due to its asymptomatic nature in early phases. PDAC has a poor prognosis, with a five-year survival rate remaining low despite advances in treatment.

Pancreatic Ductal Adenocarcinoma Symptoms typically appear in later stages and include jaundice (yellowing of the skin and eyes), unexplained weight loss, abdominal or back pain, loss of appetite, nausea, and new-onset diabetes. Risk factors include smoking, chronic pancreatitis, obesity, diabetes, family history of pancreatic cancer, and genetic mutations like BRCA1 and BRCA2.

Pancreatic Ductal Adenocarcinoma Diagnosis involves imaging techniques such as CT scans, MRI, endoscopic ultrasound (EUS), and biopsy confirmation. Tumor markers like CA 19-9 may aid in monitoring but are not definitive for diagnosis. Treatment options depend on disease stage and include surgical resection (Whipple procedure) for eligible patients, chemotherapy, radiation therapy, and targeted therapies.

Due to its aggressive nature, early detection remains a challenge, making research into novel treatment strategies and biomarker development crucial for improving patient outcomes.

Pancreatic Ductal Adenocarcinoma Emerging Drugs Profile
• Onvansertib: Cardiff Oncology
Onvansertib, an oral highly-selective PLK1 inhibitor, which we are evaluating in combination with standard-of-care (SOC) therapeutics in clinical programs targeting indications such as KRAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, and metastatic castrate-resistant prostate cancer. These programs and our broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SOC.

• Nadunolimab: Cantargia
Nadunolimab is a humanised monoclonal antibody lacking fucose, being developed by Cantargia, for the treatment of solid tumours, including non-small cell lung cancer (NSCLC) and pancreatic cancer. Nadunolimab is a first-in-class anti-IL1RAP antibody, currently evaluated with standard of care chemotherapy or checkpoint inhibitor in five phase I/II clinical trials with a primary focus on PDAC and NSCLC. Nadunolimab induces ADCC and blocks signaling of both IL-1α and IL-1β, counteracting thecontribution of IL-1 to the immune suppressive tumor microenvironment and development of resistance to chemotherapy

• Zimberelimab: Arcus Biosciences
Zimberelimab is a monoclonal antibody that binds pd-1 restoring the antitumor activity of T-cells. Zimberelimab was in-licensed by Arcus to enable the development of precision combination regimens with The most advanced study with zimberelimab is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer, evaluating zimberelimab in combination with domvanalimab, an anti-TIGIT monoclonal antibody, and etrumadenant, the first and only dual A2a/A2b adenosine receptor antagonist in the clinic. Zimberelimab is also being evaluated as monotherapy in a tumor agnostic, biomarker-selected Phase 1b trial for cancers with no approved anti-PD-1 treatment options. full line-of-sight to the commercialization of innovative therapies for all patients who may benefit.

Learn more about Pancreatic Ductal Adenocarcinoma Drugs opportunities in our groundbreaking A Pancreatic Ductal Adenocarcinoma Research and development projects @ Pancreatic Ductal Adenocarcinoma Unmet Needs- https://www.delveinsight.com/sample-request/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Pancreatic Ductal Adenocarcinoma Companies
Cardiff Oncology, XOMA, Alphamab, Cantargia, RenovoRx, Syntrix Biosystems, Eucure Biopharma, Panbela Therapeutics, Jeil Pharmaceutical, Elicio Therapeutics, Cend Therapeutics, SignalChem Lifesciences, Bristol-Myers Squibb, AstraZeneca, REVOLUTION Medicines, Arcus Biosciences, ZielBio, Surface Oncology, Incyte Corporation, I-Mab Biopharma, Medicenna Therapeutics, Tarveda Therapeutics, and others.

Pancreatic Ductal Adenocarcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
• Oral
• Intravenous
• Subcutaneous

Pancreatic Ductal Adenocarcinoma Products have been categorized under various Molecule types such as
• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Discover the latest advancements in Pancreatic Ductal Adenocarcinoma Treatment by visiting our website. Stay informed about how we're transforming the future of oncology disease @ Pancreatic Ductal Adenocarcinoma Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Pancreatic Ductal Adenocarcinoma Pipeline Report
• Coverage- Global
• Pancreatic Ductal Adenocarcinoma Companies- Cardiff Oncology, XOMA, Alphamab, Cantargia, RenovoRx, Syntrix Biosystems, Eucure Biopharma, Panbela Therapeutics, Jeil Pharmaceutical, Elicio Therapeutics, Cend Therapeutics, SignalChem Lifesciences, Bristol-Myers Squibb, AstraZeneca, REVOLUTION Medicines, Arcus Biosciences, ZielBio, Surface Oncology, Incyte Corporation, I-Mab Biopharma, Medicenna Therapeutics, Tarveda Therapeutics, and others.
• Pancreatic Ductal Adenocarcinoma Therapies- Zimberelimab, Quemliclustat, Onvansertib, Nanoliposomal irinotecan, Leucovorin, mFOLFIRINOX, and others.
• Pancreatic Ductal Adenocarcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Pancreatic Ductal Adenocarcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Pancreatic Ductal Adenocarcinoma Pipeline on our website @ Pancreatic Ductal Adenocarcinoma Drugs and Companies- https://www.delveinsight.com/sample-request/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Content
1. Introduction
2. Executive Summary
3. Pancreatic Ductal Adenocarcinoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Pancreatic Ductal Adenocarcinoma- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. NIS 793: XOMA
9. Drug profiles in the detailed report.....
10. Mid Stage Products (Phase II)
11. CEND 1: Cend Therapeutics
12. Drug profiles in the detailed report.....
13. Early Stage Products (Phase I/II)
14. DCC-3116: Deciphera Pharmaceuticals
15. Drug profiles in the detailed report.....
16. Early Stage Products (Phase I)
17. RMC-6236: REVOLUTION Medicines
18. Drug profiles in the detailed report.....
19. Inactive Products
20. Pancreatic Ductal Adenocarcinoma Key Companies
21. Pancreatic Ductal Adenocarcinoma Key Products
22. Pancreatic Ductal Adenocarcinoma- Unmet Needs
23. Pancreatic Ductal Adenocarcinoma- Market Drivers and Barriers
24. Pancreatic Ductal Adenocarcinoma- Future Perspectives and Conclusion
25. Pancreatic Ductal Adenocarcinoma Analyst Views
26. Pancreatic Ductal Adenocarcinoma Key Companies
27. Appendix

Trending Reports:
• Phosphoglucomutase Pgm 1 Deficiency Market: https://www.delveinsight.com/report-store/phosphoglucomutase-pgm-1-deficiency-market
• Polypoidal Choroidal Vasculopathy Market: https://www.delveinsight.com/report-store/polypoidal-choroidal-vasculopathy-market
• Tay-sachs Disease Or Gm2 Gangliosidosis Market: https://www.delveinsight.com/report-store/tay-sachs-disease-pipeline-insight
• Fibromyalgia Market: https://www.delveinsight.com/report-store/fibromyalgia-market
• Dermal Erythema Market: https://www.delveinsight.com/report-store/cutaneous-lupus-erythematosus-market
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/external-defibrillators-market
• Androgenetic Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Hyperhidrosis Market: https://www.delveinsight.com/report-store/axillary-hyperhidrosis-ahh-market
• Palmar Hyperhidrosis Market: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-market
• Chronic Lymphocytic Leukemia Cll Market: https://www.delveinsight.com/report-store/chronic-lymphocytic-leukemia-cll-market
• Neuromodulation Devices Market: https://www.delveinsight.com/report-store/neuromodulation-devices-market
• Catheter-related Bloodstream Infections Market: https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-market
• Chronic Myelogenous Leukemia Market: https://www.delveinsight.com/report-store/chronic-myeloid-leukemia-market
• Fuchs Dystrophy Market: https://www.delveinsight.com/report-store/fuchs-endothelial-corneal-dystrophy-fecd-market
• Graft Versus Host Disease Market: https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market
• Minimal Residual Disease Market: https://www.delveinsight.com/report-store/minimal-residual-disease-market
• Neurostimulation Devices Market: https://www.delveinsight.com/report-store/neurostimulation-devices-market
• Pressure Ulcers Market: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Progressive Multifocal Leukoencephalopathy Market: https://www.delveinsight.com/report-store/progressive-multifocal-leukoencephalopathy-market
• Acoustic Neuroma Market: https://www.delveinsight.com/report-store/acoustic-neuroma-market
• Apheresis Market: https://www.delveinsight.com/report-store/apheresis-market
• Bone Anchored Hearing Systems Market: https://www.delveinsight.com/report-store/bone-anchored-hearing-systems-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/report-store.php
AACR Conference Coverage: https://www.delveinsight.com/aacr-annual-meeting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.